Stock 4523 EISAI CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Eisai Co., Ltd.

Equities

4523

JP3160400002

Delayed Japan Exchange
Other stock markets
 07:28:20 02/05/2024 am IST 		5-day change 1st Jan Change
6,524 JPY -0.38% Intraday chart for Eisai Co., Ltd. +7.13% -7.49%
24/04 Biogen beats quarterly profit estimates, Alzheimer's drug sales jump RE
23/04 Alzheimer's drug adoption in US slowed by doctors' skepticism RE

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024
AQ
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
AQ
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
RE
Alzheimer's drug adoption in US slowed by doctors' skepticism
RE
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
AQ
BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802
CI
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
AQ
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
AQ
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
AQ
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
AQ
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment
MT
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug
MT
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
AQ
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
AQ
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
CI
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
AQ
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
AQ
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
AQ
Final dividend
FA
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4523 Stock
  4. News Eisai Co., Ltd.